Article Text

Download PDFPDF
CP-045 Electronic prescribing: the development of a paediatric drug database
  1. D Terry1,
  2. F Reynolds2,
  3. A Sinclair1,
  4. J Caffrey3,
  5. A Burridge4,
  6. N Bugg5,
  7. A Hussain1,
  8. A Terry1,
  9. J Terry1,
  10. E Junaid1
  1. 1Birmingham Children’s Hospital NHS Foundation Trust, Pharmacy, Birmingham, UK
  2. 2Birmingham Children’s Hospital NHS Foundation Trust, Intensive Care Unit, Birmingham, UK
  3. 3Birmingham Children’s Hospital NHS Foundation Trust, Project Management, Birmingham, UK
  4. 4Aston University, School of Pharmacy, Birmingham, UK
  5. 5Birmingham Children’s Hospital NHS Foundation Trust, Anaesthetics, Birmingham, UK


Background A standardised electronic paediatric drug database was needed in order to aid paediatric drug dose selection within both prescribing and clinical pharmacist screening.

Purpose To determine a system of information inputs and checks to support the development of an electronic paediatric drug database (DD). The DD is designed as a clinical support tool to aid paediatric drug dose selection within both prescribing and clinical pharmacist screening.

Material and methods A multi-disciplinary team was appointed that included senior and junior medical staff, senior and junior pharmacists, pharmacy technicians, data analyst/database engineer, nursing staff and project manager. The DD was built in MS Access 2007. Information arbitration is provided by a senior oversight team consisting of the Deputy Chief Medical Officer, Chair of Drugs and Therapeutics Committee and Director of the Academic Practice Unit (a clinical pharmacist).

Results Common data sources used in clinical practice were identified as suitable for information harvesting. The DD system is based on 5 core data fields: Drug, Indication, Route, Age, and Dose; known as DIRAD. Each DIRAD is unique with processes in place to ensure they are not duplicated. Input of a draft DIRAD occurs at level 1 (L1), which is the lowest level in the 5 level process. Passage through the system to final approval at L5 requires acceptance of the DIRAD at each and every level in the process. To date (July 2014) over 3,000 DIRADs have been entered into the system representing 765 drug entities. Reference to relevant dm + d codes is allowed within the DD structure. Migration of the system to a Sequel Server (SQL) platform is planned.

Conclusion The developed 5 stage process has been successfully used to capture and validate clinical information suitable to support electronic prescribing of medicines for paediatrics.

References and/or Acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.